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Abstract
The timing of puberty is a highly polygenic childhood trait that is epidemiologically associated 
with various adult diseases. Using 1000 Genomes Project–imputed genotype data in up to 
~370,000 women, we identify 389 independent signals (P < 5 × 10−8) for age at menarche, a 
milestone in female pubertal development. In Icelandic data, these signals explain ~7.4% of the 
population variance in age at menarche, corresponding to ~25% of the estimated heritability. We 
implicate ~250 genes via coding variation or associated expression, demonstrating significant 
enrichment in neural tissues. Rare variants near the imprinted genes MKRN3 and DLK1 were 
identified, exhibiting large effects when paternally inherited. Mendelian randomization analyses 
suggest causal inverse associations, independent of body mass index (BMI), between puberty 
timing and risks for breast and endometrial cancers in women and prostate cancer in men. In 
aggregate, our findings highlight the complexity of the genetic regulation of puberty timing and 
support causal links with cancer susceptibility.
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Puberty is the developmental stage of transition from childhood to physical and sexual 
maturity, and its timing varies markedly between individuals1. This variation reflects the 
influence of genetic, nutritional and other environmental factors and is associated with the 
subsequent risks for several diseases in adult life2. Our previous large-scale genomic studies 
identified 113 independent regions associated with age at menarche (AAM), a notable 
milestone of puberty in females3,4. The vast majority of those signals have concordant 
effects on the age at voice breaking (genome-wide genetic correlation between traits rg = 
0.74), a corresponding milestone in males5. Those genetic findings implicated a diverse 
range of mechanisms in the regulation of puberty timing, identified significant enrichment of 
AAM-associated variants in/near genes disrupted in rare disorders of puberty, and 
highlighted shared etiological factors between puberty timing and metabolic disease 
outcomes2,3.
However, those previous studies were based on genome-wide association data that were 
imputed to the relatively sparse HapMap 2 reference panel or used gene-centric arrays. 
Consequently, the reported genetic signals explained only a small fraction of the population 
variance, suggesting that several hundred or thousand signals are involved3,4. Here we report 
an enlarged genomic analysis for AAM in a nearly twofold-larger sample of women than 
previously studied3 and using more densely imputed genomic data. Our findings increase by 
more than threefold the number of independently associated signals and indicate likely 
causal effects of puberty timing on risks of various sex-steroid-sensitive cancers in men and 
women.
RESULTS
Genome-wide array data, imputed to the 1000 Genomes Project reference panel, were 
available in up to 329,345 women of European ancestry. These comprised 40 studies from 
the ReproGen consortium (N = 179,117), in addition to the 23andMe (N = 76,831) and UK 
Biobank (N = 73,397) studies (Supplementary Table 1). The distribution of genome-wide 
test statistics demonstrated significant inflation (λGC = 1.75); however, linkage 
disequilibrium (LD) score regression analyses confirmed that this inflation was solely due to 
polygenicity rather than population structure (LD score intercept = 1.00, standard error (SE) 
= 0.02). In total, 37,925 variants were associated with AAM at P < 5 × 10−8, which were 
resolved to 389 statistically independent signals (Supplementary Fig. 1 and Supplementary 
Table 2). Per-allele effect sizes ranged from ~1 week to 5 months, 16 index variants were 
classed as low frequency (minor allele frequency (MAF) <5%; minimum observed 
frequency 0.5%), and 26 were insertion/deletion polymorphisms. Signals were distributed 
evenly across all 23 chromosomes with respect to chromosome size (Supplementary Fig. 2). 
Of the previously reported 106 autosomal, 5 exome array and 2 X-chromosome signals for 
AAM, all remained associated at genome-wide significance, except for two common loci 
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(reported as SCRIB–PARP10 (P = 5 × 10−4) and FUT8 (P = 5.4 × 10−7)) and one rare 
variant not captured by the 1000 Genomes Project reference panel (p.Trp275*, TACR3).
Independent replication in the deCODE study (N = 39,543 women) showed that 367 
(94.3%) of the 389 signals had directionally concordant effects (187 at P < 0.05), and 368 
retained genome-wide significance in a combined meta-analysis (Supplementary Table 3). In 
aggregate, the top 389 index SNPs explained 7.4% of the trait variance in deCODE and 
7.2% in UK Biobank (the latter estimate used weights derived from a meta-analysis 
excluding UK Biobank). These estimates are double the variance explained by the 106 
previously reported signals3 (3.7% in deCODE) and are equivalent to one-quarter of the total 
chip-captured heritability (h2SNP = 32%, SE = 1%) for AAM, estimated in UK Biobank.
Consistent with our previous reports, we found strong sharing between the genetic 
architectures of AAM in women and age at voice breaking in men (considered as a 
continuous trait in 55,871 men in 23andMe) (genetic correlation (rg) = 0.75, P = 1.2 × 
10−79). Of the 389 AAM signals, 327 demonstrated directionally consistent trends or 
associations with age at voice breaking in men (binomial P = 1.4 × 10−44), and 18 signals 
reached a conservative multiple-test-corrected significance threshold (P < 1 × 10−4; 
0.05/389) (Supplementary Table 4). Similarly, in UK Biobank where age at voice breaking 
was recorded using only three categories, 277 and 297 of the 377 autosomal loci 
demonstrated directionally consistent trends or associations with ‘relatively early voice 
breaking’ (N = 2,678 cases, N = 55,763 controls, binomial P = 2.4 × 10−20) and ‘relatively 
late voice breaking’ (N = 3,566 cases, P = 1.9 × 10−30), respectively (Supplementary Table 
5).
Implicated genes and tissues
We used a number of analytical techniques to implicate genes in the regulation of AAM. 
These included mapping of nonsynonymous SNPs, expression quantitative trait locus 
(eQTL) analysis and integration of Hi-C chromatin-interaction data. Eight of the 389 lead 
variants were nonsynonymous, and a further 24 genes were implicated by highly correlated 
nonsynonymous variants (r2 > 0.8) (Supplementary Table 6). These include genes disrupted 
in rare disorders of puberty: aromatase (CYP19A1, signal 307), gonadotropin-releasing 
hormone (GNRH1; signal 178), kisspeptin (KISS1; signal 31); and fucosyltransferase 2 
(FUT2; signal 357), in which a stop-gain variant confers blood group secretor status.
Two approaches were used to interrogate publicly available gene expression data sets, both 
of which use one or more SNPs (not restricted to lead SNPs) to infer patterns of gene 
expression based on imputation reference panels (Online Methods). First, to maximize 
power, we analyzed data from the largest available eQTL data set for any tissue (whole 
blood, N = 5,311)6, under the assumption that some causal genes and regulatory 
mechanisms might be ubiquitously expressed or functionally involved in blood tissues. 
Systematic eQTL integration using the Summary Mendelian Randomization approach7 
prioritized 113 transcripts, 60 of which had evidence for causal or pleiotropic effects, rather 
than coincidental overlap of signal (as indicated by HEIDI heterogeneity test P > 0.009) 
(Supplementary Table 7). Second, we used LD score regression applied to specifically 
expressed genes (LDSC-SEG)8 to identify tissues and cell types that are enriched for AAM 
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heritability. Five of the 46 GTEx tissues were positively enriched for AAM-associated 
variants (Fig. 1). Notably, all of these were central nervous system tissues, including the 
pituitary, and the hypothalamus was just below the significance threshold for enrichment (P 
= 9.8 × 10−3), consistent with the key role of this central axis2. Targeted assessment of these 
five enriched brain tissues using MetaXcan identified 205 genes whose expression was 
regulated by AAM-associated variants (Supplementary Table 8). Of note, later AAM was 
associated with higher transcript levels of LIN28B (signal 147) in the pituitary, NCOA6 
(nuclear receptor coactivator 6; signal 365) in the cerebellum, and HSD17B12 
(hydroxysteroid-(17-β)-dehydrogenase 12; signal 250) in various tissues.
To identify possible distal causal genes, we interrogated reported Hi-C data to assess 
whether any of the AAM loci are located in regions of chromatin looping9. 335 of the 389 
loci were located within a topologically associating domain (TAD; a defined boundary 
region containing chromatin contact points), each of which contained on average ~5 genes 
(Supplementary Table 9). These included 22 of the 31 gene desert regions (nearest protein-
coding gene >300 kb away), where TADs contained notable distal candidate genes such as 
INHBA (signal 158), BDNF (signal 248), JARID2 (signal 128) and several γ-aminobutyric 
acid receptors (signal 91). We also observed several regions where multiple independent 
AAM signals all resided within one TAD containing the same single gene—RORB (signal 
200, intronic; signal 199, ~200 kb downstream; signal 198, ~1.2 Mb downstream), THRB 
(signal 67, intronic; signal 68, ~180 kb upstream) and TACR3 (signal 96, 5′UTR; signal 97, 
~25 kb upstream; signal 98, ~133 kb upstream; signal 95, ~263 kb downstream).
Sixty-six AAM signals were located in a specific contact point (from 5–25 kb in size) within 
the 335 TADs, indicating a direct physical connection between these signals and a distal 
genomic region, on average ~320 kb away. This included the previously reported example of 
the BMI-associated (and AAM-associated) FTO SNP and a distal IRX3 promoter ~1 Mb 
away (signal 326)10. The longest chromatin interaction observed was ~38.6 Mb, where two 
distinct AAM signals, located ~300 kb apart (signals 206 and 207), were both in contact 
with the same distal genomic region ~38.6 Mb away that contains only one gene, PTGES2, 
encoding prostaglandin E synthase 2.
Transcription factor binding enrichment
To identify functional gene networks implicated in the regulation of AAM, we tested for 
enriched co-occurrence of AAM associations and predicted regulators within 226 putative 
enhancer modules, combining DNase–1 hypersensitive sites and chromatin states in 111 cell 
types and tissues. In total, we tested 2,382 transcription factor–enhancer module 
combinations. Sixteen transcription factor binding motifs were enriched for co-occurrence 
with AAM-associated variants within enhancer regions at study-level significance (false 
discovery rate (FDR) < 0.05) (Supplementary Table 10). Furthermore, 5 of the 16 genes 
encoding transcription factors associated with these motifs also mapped within 1 Mb of an 
index AAM-associated SNP. These included notable candidates; first, PITX1 (pituitary 
homeobox 1) is located within 50 kb of genome-wide significant SNPs (~500 kb from lead 
index signal 114). Second, SMAD3, a gene recently implicated in susceptibility to dizygous 
twinning11, is located within 600 kb of an index SNP and its expression in several GTEx 
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brain tissues is genetically correlated with AAM. Third, RXRB is located within ~500 kb of 
a new index SNP (signal 133), and it represents the fifth (out of nine) retinoid-related 
receptor gene implicated by genome-wide significant AAM variants. This set now includes 
all three retinoid X receptor–encoding genes (RXRA, RXRB and RXRG), and retinoid-
related receptor genes are the nearest gene to the index SNP at three AAM loci (RXRA, 
RORA and RORB).
Pathway analyses
To identify other mechanisms that regulate pubertal timing, we tested all SNPs across the 
genome for enrichment of AAM associations with genes in predefined biological pathways. 
Ten pathways reached study-wise significance (FDR < 0.05). Five pathways were related to 
transcription factor binding, and the other pathways were peptide hormone binding, PI3-
kinase binding, angiotensin-stimulated signaling, neuron development and γ-aminobutyric 
acid (GABA)-type B receptor signaling (Supplementary Table 11).
All of our previously reported custom pathways (Supplementary Table 12)3 remained 
significant in this expanded data set: nuclear hormone receptors (P = 2.4 × 10−3); Mendelian 
pubertal disorder genes (P = 1.9 × 10−3); and JmjC-domain-containing lysine-specific 
demethylases (P = 1 × 10−4). Notably, new genome-wide significant signals mapped to 
lysine-specific demethylase genes: JMJD1C (signal 223), PHF2 (208), KDM4B (347), 
KDM6B (332) and JARID2 (128); or to Mendelian pubertal disorder genes: CYP19A1 
(307), FGF8 (230), GNRH1 (178), KAL1 (378), KISS1 (31), NR5A1 (215) and NR0B1 
(379). The strongest AAM signal remained at LIN28B3,12,13, which encodes a key repressor 
of let-7 microRNA (miRNA) biogenesis and cell pluripotency14. Transgenic Lin28a/b mice 
demonstrate both altered pubertal growth and glycaemic control15, suggesting that the 
LIN28–let-7 axis could link puberty timing to type 2 diabetes susceptibility in humans. let-7 
miRNA targets are reportedly enriched for variants associated with type 2 diabetes16. We 
tested the same set of computationally predicted and experimentally derived mRNA/protein 
let-7 miRNA targets16 and observed significant enrichment of AAM-associated variants at 
miRNA targets that are downregulated by let-7b overexpression in primary human 
fibroblasts (Pmin = 1 × 10−3; Supplementary Table 12).
Imprinted genes and parent-of-origin effects
We previously reported an excess of parent-of-origin-specific associations for those AAM 
variants that map near imprinted genes, as defined primarily from animal studies3. Recent 
data from the GTEx consortium now allow a more systematic assessment of imprinted gene 
enrichment using genes defined from human transcriptome-wide analyses17. Consistent with 
our previous observations, imprinted genes were enriched for AAM-associated variants 
(MAGENTA P = 4 × 10−3), with a concordant excess of parent-of-origin-specific 
associations for the 389 index AAM variants (Supplementary Fig. 3 and Supplementary 
Table 3).
Systematic assessment of the 389 AAM gene regions in the Icelandic deCODE study 
identified rare variants in two imprinted gene regions with robust parent-of-origin-specific 
associations with AAM. First, we identified a rare 5′ UTR variant, rs530324840 (MAF = 
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0.80% in Iceland), in MKRN3 that was associated with AAM under the paternal model (P = 
6.4 × 10−11, β = −0.52 years) but not the maternal model (P = 0.20, β = 0.098; Phet = 1.3 × 
10−7) (Table 1 and Supplementary Table 13). rs530324840 was by far the most significant 
variant at the MKRN3 locus and is uncorrelated with our previously reported common 
variant rs12148769 at the same locus (r2 < 0.001 in deCODE)3 (Supplementary Fig. 4). We 
note that the rare 5′ UTR variant rs184950120 detected in the current genome-wide 
association study (GWAS) meta-analysis also showed paternal-specific association in 
deCODE and, despite being in close proximity (235 bp from rs530324840), is uncorrelated 
with rs530324840 (r2 < 0.0001 in deCODE).
The second new robust parent-of-origin-specific signal is indicated by a rare intergenic 
variant at the DLK1 locus (rs138827001; MAF = 0.36% in Iceland) that associated with 
AAM under the paternal model (P = 4.7 × 10−10, β = −0.70 years) but not the maternal 
model (P = 0.88, β = −0.018 years; Phet = 1.4 × 10−4) (Table 1 and Supplementary Fig. 5). 
rs138827001 is uncorrelated with the two previously reported common variants rs10144321 
and rs7141210 at the DLK1 locus (r2 < 0.01 in Iceland) that both also showed paternal-
allele-specific associations3. At this locus, we observed a further common variant, 
rs61992671 (MAF = 48.5% in Iceland), 4.4 kb upstream of the MEG9 (maternally expressed 
9) gene (~300 kb from DLK1) that was associated with AAM under the maternal model (P = 
6.0 × 10−8, β = −0.077 years) but not the paternal model (P = 0.27, β = 0.015 years; Phet = 
1.9 × 10−5). rs61992671 is uncorrelated (r2 < 0.05) with the two common signals identified 
in the meta-analysis (rs10144321 and rs7141210) and replicated with a consistent magnitude 
of effect in our GWAS meta-analysis (additive model, P = 5.1 × 10−6).
Disproportionate genetic effects on early or late puberty timing
Family-based studies in twins have suggested age-related differences in the impacts of 
genetic and environmental factors on AAM18. To test for asymmetry in the genetic effects 
on puberty timing, we defined two groups of women in the UK Biobank study on the basis 
of approximated quintiles for AAM—‘early’ (8–11 years inclusive; N = 14,922) and ‘late’ 
(15–19 years; N = 12,290). Each group was compared to the same median-quintile AAM 
reference group (age 13; N = 17,717). Estimated genome-wide heritability was higher for 
early AAM (h2SNP = 28.8%, SE = 2.3%) than for late AAM (h2SNP = 21.5%, SE = 2.5%; 
Pdif = 0.03). Accordingly, 217 of 377 (57.7%) autosomal index SNPs had larger effect 
estimates on early than on late AAM (binomial P = 0.004 versus 50% expected), and the 
aggregated effect of the 377 SNPs also differed between strata (P = 2.3 × 10−4) (Fig. 2 and 
Supplementary Table 14). These differences remained when matching the early- and late-
AAM strata for sample size and phenotype ranges (Supplementary Table 15).
In contrast, we observed the opposite pattern of disproportion in the genetic effects on male 
voice breaking in UK Biobank (‘relatively early’ N = 2,678, ‘relatively late’ N = 3,566). 
Genome-wide heritability estimates tended to be higher for relatively late voice breaking 
(7.8%, SE = 1.2%) than for relatively early voice breaking (6.9%, SE = 1.3%), and 227 of 
377 (60.2%) index SNPs had larger effect estimates for relatively late than on relatively 
early voice breaking (binomial P = 4.3 × 10−5).
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BMI-independent effects of puberty timing on cancer risks
Traditional (non-genetic) epidemiological studies have reported complex associations 
between puberty timing, BMI and adult cancer risks. For example, large studies using 
historical growth records identified lower adolescent BMI and earlier puberty timing 
(estimated by the age at peak adolescent growth) as predictors of higher breast cancer risk in 
women19,20. Conversely, BMI is positively associated with breast cancer risk in 
postmenopausal women21. Furthermore, the strong inter-relationship between puberty 
timing and BMI limits the ability to consider their distinct influences on disease risks in 
traditional observational studies. Consistent with our previous report5, we observed a strong 
inverse genetic correlation between AAM and BMI (rg = −0.35, P = 1.6 × 10−72). Thirty-
nine AAM loci overlapped with reported loci for adult BMI22, yet even those AAM signals 
with weak individual associations with adult BMI still contributed to BMI when considered 
in aggregate: the 237 AAM variants without a nominal individual association with adult 
BMI (all P > 0.05) were collectively associated with adult BMI (P = 4.2 × 10−9) 
(Supplementary Fig. 6). This finding precludes an absolute distinction between BMI-related 
and BMI-unrelated AAM variants.
In Mendelian randomization analyses, we therefore included adjustment for genetically 
predicted BMI (as predicted by the 375 autosomal AAM variants) to assess the likely direct 
(BMI-independent) effects of AAM on the risks for various sex-steroid-sensitive cancers 
(Online Methods). In these BMI-adjusted models, increasing AAM was associated with 
lower risk for breast cancer (odds ratio (OR) = 0.935 per year, 95% confidence interval (CI) 
= 0.894–0.977; P = 2.6 × 10−3) and in particular with estrogen receptor (ER)-positive but not 
ER-negative breast cancer (Phet = 0.02) (Fig. 3 and Supplementary Table 16). Similarly, 
increasing AAM adjusted for genetically predicted BMI was associated with lower risks for 
ovarian cancer (OR = 0.930, 95% CI = 0.880–0.982; P = 9.3 × 10−3), in particular serous 
ovarian cancer (OR = 0.917, 95% CI = 0.859–0.978; P = 8.9 × 10−3) and endometrial cancer 
(OR = 0.781, 95% CI = 0.699–0.872; P = 9.97 × 10−6). Assuming an equivalent per-year 
effect of the current AAM variants on age at voice breaking, as we reported for the 106 
previously identified AAM variants5, we could also infer a protective effect of later puberty 
timing, independent of BMI, on risk for prostate cancer in men (OR = 0.925, 95% CI = 
0.876–0.976; P = 4.4 × 10−3).
These findings were supported by sensitivity tests using subgroups of AAM signals stratified 
by their individual associations with adult BMI. The BMI-unrelated variant score 
(comprising 314 variants) supported a direct effect of AAM timing on breast cancer risk in 
women (OR = 0.946, 95% CI = 0.904–0.988; P = 1.3 × 10−2). In contrast, a score using only 
the 61 BMI-related AAM variants gave a significant result in the opposite direction (OR = 
1.15, 95% CI = 1.06–1.25; P = 4.3 × 10−4) (Supplementary Table 16), consistent with the 
recently reported inverse association between genetically predicted BMI and breast cancer 
risk23,24. Further sensitivity tests (heterogeneity and MR-Egger tests) using the BMI-
unrelated variant score suggested that additional subpathways might link AAM to risk of 
ovarian cancer (MR-Egger intercept P = 0.036), but, reassuringly, these tests indicated no 
further pleiotropy (beyond the effects of BMI) in our analyses of breast, endometrial and 
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prostate cancers (for all, I2 < 23% and MR-Egger intercept P > 0.1) (Supplementary Fig. 7 
and Supplementary Table 16).
DISCUSSION
In a substantially enlarged genomic analysis using densely imputed genomic data, we have 
identified 389 independent, genome-wide significant signals for AAM. In aggregate, these 
signals explain ~7.4% of the population variance in AAM, corresponding to ~25% of the 
estimated heritability. While assigning possible causal genes to associated loci is an ongoing 
challenge for GWAS findings, we adopted a number of recently described methods to 
implicate the underlying genes and tissues. Thirty-three genes were implicated by 
nonsynonymous variants and >200 genes were implicated by transcriptome-wide association 
in the five neural tissues enriched for AAM-associated gene activation. Transcriptome-wide 
association analyses also enabled the estimation of direction of gene expression in relation to 
AAM, notably indicating the likely delaying effect of LIN28B gene expression on AAM, 
which is consistent with inhibitory effects of this gene on developmental timing in animal 
and cell models14,15.
Our findings add to the growing evidence for a significant role of imprinted genes in the 
regulation of puberty timing3. In a recent family study, rare coding mutations (two 
frameshift, one stop gain and one missense) in MKRN3 were shown to cause central 
precocious puberty when paternally inherited25. Taken together, three distinct types of 
variants at MKRN3 appear to influence puberty timing when paternally inherited: (i) 
multiple rare loss-of-function mutations with large effects25; (ii) a common intergenic 
variant (rs530324840) with small effect; and (iii) two 5′ UTR variants (rs184950120 and 
rs12148769) with intermediate allele frequencies (1 in 95 Icelandic women) and effects 
(~0.5 years per allele). Similarly, we found allelic heterogeneity at the imprinted DLK1 
locus where, as at MKRN3, a low-frequency paternally inherited allele conferred a 
substantial decrease in the age of puberty timing. At the same locus, maternal-allele-specific 
association with an unrelated variant near the maternally expressed gene MEG9 is consistent 
with multiple imprinting control centers at this imprinted gene cluster26.
The strong collective influence of the identified loci on AAM allowed informative 
stratification of AAM-associated variants in causal analyses to distinguish between BMI-
related and BMI-unrelated pathways linking puberty timing to risk of sex-steroid-sensitive 
cancers. These findings were supported in BMI-adjusted models and, except for ovarian 
cancer, by additional tests for pleiotropy and indicate causal influences of both lower 
adolescent BMI and earlier AAM on later cancer risks. The association between BMI and 
breast cancer risk is complex; directionally opposing associations have been reported with 
adolescent and adult BMI, and with differing associations with pre- and postmenopausal 
breast cancer19–21. Recent Mendelian randomization studies report a consistent protective 
effect of higher BMI on pre- and postmenopausal breast cancer23,24. Some studies have 
reported on the association between later puberty timing and lower risk of prostate cancer in 
men, but such data on puberty timing in men are scarcely recorded27. The influences of 
earlier puberty timing, independent of BMI, on higher risks of breast, ovarian and 
endometrial cancers in women and prostate cancer in men could be mediated by a longer 
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duration of exposure to sex steroids. Alternatively, mechanisms that confer earlier puberty 
timing might also promote higher levels of hypothalamic–pituitary–gonadal axis activity, as 
exemplified by a variant in FSHB that confers earlier AAM, higher circulating follicle-
stimulating hormone concentrations in women and higher susceptibility to dizygous 
twinning11.
We identified disproportionate effects of AAM variants on early or late puberty timing in a 
sex-discordant pattern. In females, variant effect estimates and heritability were higher for 
early versus late puberty timing, but the opposite was seen in males. These findings are 
concordant with clinical observations of sex-dependent penetrance of abnormal early and 
late puberty timing, even when accounting for presentation bias. Girls are more susceptible 
than boys to start puberty at abnormally young ages28, whereas boys are more susceptible 
than girls to have delayed onset of puberty29. These findings suggest some yet-to-be-
identified sex-specific gene–environment interactions. Future studies should systematically 
explore the potential influence of AAM-associated variants on rare disorders of puberty. In 
summary, our findings suggest unprecedented genetic complexity in the regulation of 
puberty timing and support new causal links with susceptibility to sex-steroid-sensitive 
cancers in women and men.
ONLINE METHODS
GWAS meta-analysis for age at menarche in women
Each individual study tested SNPs using a two-tailed additive linear regression model for 
association with AAM, including age at study visit and other study-specific covariates. 
Insertion/deletion polymorphisms were coded as “I” and “D” for data storage efficiency and 
to allow harmonization across all studies. Genetic variants and individuals were filtered on 
the basis of study-specific quality control metrics. Association statistics for each SNP were 
then uploaded by study analysts for central processing. Study-level results files were 
assessed following a standardized quality control pipeline30, and results for each SNP were 
subjected to meta-analysis across studies using an inverse-variance-weighted model with 
METAL31 in a two-stage process. First, results from ReproGen consortium studies 
(Supplementary Table 1) were combined and then filtered so that only SNPs that appeared in 
over half of these studies were taken forward. Second, aggregated ReproGen consortium 
results were combined with data from the UK Biobank32,33 and 23andMe5 studies. Variants 
were only included in the final results file if they had results from at least two of these three 
sources, and combined MAF >0.1%. We assessed potential inflation of test statistics due to 
sample relatedness and population stratification using LD score regression34. Here an 
intercept value not significantly different from 1 indicates no such inflation, with a value 
over 1 indicating inflation.
A final list of index variants was first defined using a distance-based metric, by which any 
SNPs passing the two-tailed threshold of significance (P < 5 × 10−8) within 1 Mb of another 
significant SNP were considered to be located in the same locus. This list of signals was 
then further augmented using approximate conditional analysis in GCTA, using an LD 
reference panel from the UK Biobank study. Only secondary signals that were uncorrelated 
(r2 < 0.05) were included in the final list.
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Replication and parent-of-origin testing
Replication of identified hits was performed in an independent sample of 39,486 women of 
European ancestry from the deCODE study, Iceland. Main effects and parent-of-origin 
association testing were performed using the same methodology as previously reported3,4. 
The fraction of variance explained by a variant associating under the additive model was 
calculated using the formula , where f denotes the MAF of the variant and βa is 
the additive effect. For variants associating under the recessive model, the formula 
 was used, where fh denotes the homozygous frequency of the variant and βr 
denotes the recessive effect. For variants associating under parent-of-origin models, fraction 
of variance explained was computed using the formulas  for the maternal model 
and  for the paternal model, where f denotes the MAF of the variant, βm denotes 
the effect under the maternal model and βp denotes the effect under the paternal model. 
Variance explained across multiple SNPs was calculated by summing the individual 
variances for all uncorrelated variants. We also estimated variance explained for top hits in 
UK Biobank using a combined allele score of all 377 autosomal genetic variants. Each 
individual variant was weighted using effect estimates derived from a meta-analysis 
excluding UK Biobank.
Age at voice breaking in men
Data on male voice breaking were available from two sources. First, the 23andMe study 
recorded recalled age at voice breaking in a sample of 55,871 men, as previously described5. 
This was recorded as a quantitative trait into predefined 2-year age bins by online 
questionnaire in response to the question “How old were you when your voice began to 
crack/deepen?” (ref. 5). Individual SNP effect estimates from the 2-year age bins were 
rescaled to 1-year estimates for both voice breaking and AAM as reported previously.
Age at voice breaking was also recalled in the UK Biobank study, as previously described33. 
This was recorded as a categorical trait—“younger than average,” “about average age,” 
“older than average,” “do not know” or “prefer not to answer”—in response to the question 
“When did your voice break?” In separate models, the earlier or later voice breaking groups 
were compared to the average group (used as the reference group).
Disproportionate effects on early or late puberty timing
Disproportionate effects on early or late puberty timing of AAM-associated SNPs were 
tested for AAM in UK Biobank. The distribution of AAM was divided into approximate 
quintiles, as previously reported33. Odds ratios for being in the youngest quintile (range 8–
11 years) or the oldest quintile (range 15–19 years) were compared to the middle quintile 
(age 13 years) as the reference, for each AAM-associated SNP and also for a combined 
weighted AAM-increasing allele score, with weights derived from a meta-analysis of all 
studies except UK Biobank. Sensitivity tests were performed by dividing UK Biobank 
individuals into broad strata on the basis of birth year (before or after 1950) and 
geographical location (attendance at a study assessment center in the north or south of the 
UK, as indicated by a line joining Mersey and Humber).
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Genetic correlation and genome-wide variance analysis
Genome-wide genetic correlations with adult BMI22 and voice breaking5 were estimated 
using LD score regression implemented in LDSC34. The total trait variance of all genotyped 
SNPs was calculated using restricted estimate maximum likelihood (REML) implemented in 
BOLT35. This was estimated using the same UK Biobank study sample in the discovery 
analysis, excluding any related individuals. The proportion of the heritability explained by 
index SNPs was estimated by dividing the variance explained by the index SNPs by the total 
variance explained by all genotyped SNPs across the genome.
Mendelian randomization analyses
Individual genotype data on cancer outcomes were available from the Breast Cancer 
Association Consortium (BCAC) and the Endometrial Cancer Association Consortium 
(ECAC). In addition, summary-level results for ovary and prostate cancer were made 
available from the Ovarian Cancer Association Consortium (OCAC) and the Prostate Cancer 
Association Group to Investigate Cancer-Associated Alterations in the Genome 
(PRACTICAL) consortium, respectively. Total analyzed numbers were as follows: 47,800 
breast cancer cases and 40,302 controls, 4,401 endometrial cancer cases and 28,758 controls, 
18,175 ovarian cancer cases and 26,134 controls, and 20,219 prostate cancer cases and 
20,440 controls (from the PRACTICAL iCOGS data set).
We performed Mendelian randomization analyses to assess the likely causal effects of 
puberty timing on the risks for various sex-steroid-sensitive cancers. Hence, AAM was 
predicted by a weighted genetic risk score of all 375 autosomal AAM-associated SNPs, and 
genetically predicted AAM was tested for association with each cancer in a logistic 
regression model. The individual SNP genotype dosages comprising this score were imputed 
using the 1000 Genomes Project reference panel (minimum imputation r2 = 0.43, median = 
0.95). To avoid potential confounding by effects of the AAM genetic risk score on BMI, we 
performed BMI-adjusted analyses by including the same AAM genetic risk score in models 
as a covariate, but weighting each SNP for its effect on BMI (rather than on AAM) in the 
same study sample. Hence, we estimated the effect of genetically predicted AAM, 
controlling for genetically predicted BMI by the same SNPs. BMI weighting was based on 
the association between each SNP and adult BMI in this sample (childhood BMI 
measurements were not available, but there is reportedly high genetic correlation between 
adult and childhood obesity (rg = 0.73)36. We did not adjust for measured BMI because such 
measurements in prevalent cancer cases are likely to introduce bias. As sensitivity tests, 
three further genetic score associations were performed for each cancer outcome: first, AAM 
predicted by the 314 AAM-associated SNPs that were not also individually associated with 
BMI in the BCAC iCOGS sample (at a nominal level of P < 0.05); second, AAM predicted 
by the 61 AAM-associated SNPs that were also associated with BMI in this sample (P < 
0.05); and, finally, AAM predicted by all 375 autosomal AAM-associated SNPs (unadjusted 
for BMI). To further consider pleiotropy, we tested for the presence of heterogeneity 
between AAM-associated SNPs and analyzed MR-Egger regression models37.
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MAGENTA was used to explore pathway-based associations in the full GWAS data set. 
MAGENTA implements a gene set enrichment analysis (GSEA)-based approach, as 
previously described38. Briefly, each gene in the genome is mapped to a single index SNP 
with the lowest P value within a 110 −kb upstream, 40-kb downstream window. This P 
value, representing a gene score, is then corrected for confounding factors such as gene size, 
SNP density and LD-related properties in a regression model. Genes within the human 
leukocyte antigen (HLA) region were excluded from analysis because of difficulties in 
accounting for gene density and LD patterns. Each mapped gene in the genome is then 
ranked by its adjusted gene score. At a given significance threshold (95th and 75th 
percentiles of all gene scores), the observed number of gene scores in a given pathway with 
a ranked score above the specified threshold percentile is calculated. This observed statistic 
is then compared to 1,000,000 randomly permuted pathways of identical size. This generates 
an empirical GSEA P value for each pathway. Significance was determined when an 
individual pathway reached FDR < 0.05 in either analysis. In total, 3,216 pathways from 
Gene Ontology, PANTHER, KEGG and Ingenuity were tested for enrichment of multiple 
modest associations with AAM. MAGENTA software was also used for enrichment testing 
of custom gene sets.
Gene expression data integration
To identify which tissues and cell types were likely to be most relevant to genes involved in 
pubertal development, we applied LD score regression39 to specifically expressed genes 
(LDSC-SEG)8. For each tissue, we ranked genes by a t statistic for differential expression, 
using sex and age as covariates and excluding all samples in related tissues. For example, we 
compared expression in hippocampus samples to expression in all non-brain samples. We 
then took the top 10% of genes by this ranking, formed a genome annotation including these 
genes (exons and introns) plus 100 kb on either side, and used stratified LD score regression 
to estimate the contribution of this annotation to per-SNP AAM heritability, adjusting for all 
categories in the baseline model39. We computed significance using a block jackknife over 
SNPs and corrected for 46 hypotheses tested at P = 0.05.
To identify specific eQTL-linked genes, we used two complementary approaches to 
systematically integrate publicly available gene expression data with our genome-wide data 
set: summary mendelian randomization (SMR) and MetaXcan.
SMR uses summary-level gene expression data to map potentially functional genes to trait-
associated SNPs7. We ran this approach against the publicly available whole-blood eQTL 
data set published by Westra et al.6, giving association statistics for 5,950 transcripts. A 
conservative significance threshold was set at P < 8.4 × 10−6, in addition to a HEIDI test 
statistic P > 0.009 for any variants that surpass the main threshold.
MetaXcan, a meta-analysis extension of the PrediXcan method40, was used to infer the 
association between genetically predicted gene expression (GPGE) and AAM. PrediXcan is 
a gene-based data aggregation and integration method that incorporates information from 
gene expression and GWAS data to translate evidence of association with a phenotype from 
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the SNP level to the gene. Briefly, PrediXcan first imputes gene expression at an individual 
level using prediction models trained on measured transcriptome data sets with genome-
wide SNP data and then regresses the imputed transcriptome levels with the phenotype of 
interest. MetaXcan extends its application to allow inference of the direction and magnitude 
of GPGE–phenotype associations with only summary GWAS statistics, which is 
advantageous when SNP–phenotype associations result from a meta-analysis setting and 
also when individual-level data are not available. As input, we used GWAS meta-analysis 
summary statistics for AAM, LD matrix from the 1000 Genomes Project and, as weights, 
gene expression regression coefficients for SNPs from models trained with transcriptome 
data (V6p) from the GTEx Project41. GTEx is a large-scale collaborative effort where DNA 
and RNA from multiple tissues were sequenced from almost 1,000 deceased individuals of 
European, African and Asian ancestry. MetaXcan analyses were targeted to those tissue 
types with previous evidence of association with AAM (based on the GTEx enrichment 
analyses described above). The threshold for statistical significance was estimated using the 
Bonferroni method for multiple-testing correction across all tested tissues (P < 2.57 × 10−6).
Motif enrichment testing
We identified transcription factors whose binding could be disrupted by AAM-associated 
variants in enhancer regions by combining predicted enhancer regions across 111 human cell 
types and tissues with predicted motif instances for 651 transcription factor families as 
previously described42.
Briefly, we defined enhancer regions by first applying ChromHMM43, training a 15-state 
model for each reference epigenome on 5 histone modifications: H3K4me1, H3K4me3, 
H3K36me3, H3K9me3 and H3K27me3. We then produced a higher-confidence set of 
predicted enhancer regions in each reference epigenome by intersecting DNase I 
hypersensitive sites (taking the union over 53 reference epigenomes for which DNase–seq 
was performed) with enhancer-like chromatin states predicted in that reference epigenome42. 
We defined 226 disjoint enhancer modules with distinct patterns of activity by hierarchically 
clustering the high-confidence regions according to their patterns of activity (presence/
absence) across the 111 reference epigenomes.
We predicted motif instances by first building a database of position weight matrices 
(PWMs) combining known motifs from Transfac and Jaspar with de novo–discovered motifs 
in 427 ChIP–seq experiments for 123 transcription factors from ENCODE44. We predicted 
active regulators in each enhancer module by computing the enrichment of true PWM 
matches in the set of regions assigned to that module against the background of shuffled 
PWM matches. We only considered PWMs with a conservation score of at least 0.3 and used 
log2 (fold enrichment) > 1.5 as the significance cutoff.
We used the full set of AAM association summary statistics, excluding the 23andMe 
component, to identify a heuristic P-value threshold42. Briefly, we pruned a set of 8,094,080 
variants to 432,550 independent loci (pairwise r2 < 0.1). We scored each locus as the 
proportion of variants in the locus overlapping a predicted enhancer region, ranked loci by 
the best P value in the locus and then plotted enrichment curves comparing the cumulative 
score every 100 loci against the expected score for that total number of loci under the null 
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where the score increases uniformly to the genome-wide value. We defined the right-most 
elbow point (inflection point) among all the enrichment curves as the heuristic P-value 
cutoff.
For each combination of enhancer module and predicted regulator, we constructed a 2 × 2 
contingency table counting enhancer regions in that module partitioned by presence of that 
motif and orthogonally by presence of an AAM association (based on the heuristic P-value 
cutoff described above). We restricted the set of regions to the domain on which motifs were 
discovered (excluding coding regions, 3′ UTRs, transposons and repetitive regions) and 
additionally to the subset of regions that harbor an imputed SNP for the disease. We 
computed one-sided P values using Fisher’s exact test.
Hi-C integration
Significant Hi-C interactions and contact domains were obtained from Rao et al. (GEO 
accession GSE63525) for six ENCODE cell lines: K562, GM12878, HeLa-S3, IMR90, 
NHEK and HUVEC. Their Juicer pipeline assigns statistical significance to each Hi-C 
interaction at resolutions ranging from 5–25 kb, depending on coverage, at a 10% FDR. 
Contact domains are genomic regions enriched for regulatory interactions and are more 
conserved across cell types than are specific interactions. They are conceptually similar to 
TADs, but with improved resolution (median length of 185 kb versus 880 kb). We used the 
intersect command of BEDtools to produce a list of significantly interacting Hi-C fragments 
containing one or more of our identified SNPs in either fragment from any of the six cell 
lines. For each SNPcontaining fragment, genes present in the corresponding interacting 
fragment were identified as potential regulatory targets. As a second approach, we also 
scored genes on the basis of the number of ENCODE cell types in which they were in the 
same contact domain as a SNP.
Data availability
GWAS meta-analysis summary statistics from the ReproGen consortium are available to 
download from the ReproGen website (http://www.reprogen.org/).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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GTEx tissue enrichment using LD score regression. Numbers on the x axis correspond to 
sample number for each tissue. The dashed line represents significance at FDR < 5%, and 
the solid horizontal line represents Bonferroni-corrected significance for the number of 
tissues tested.
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Stronger effects of AAM-associated signals on early menarche than late menarche in 
women. The 377 index AAM-associated SNPs are ordered from smallest to largest P value 
for their continuous association with AAM. The y axis shows the log-transformed odds ratio 
for each SNP on early menarche (blue; ages 8–11 years, inclusive) or late menarche (red; 
ages 15–19 years, inclusive). The reference group comprises women with menarche at 13 
years. Insert, −log10 P values for heterogeneity (based on Cochran’s Q) between the 
associations for early and late menarche plotted against the −log10 P value for the 
continuous AAM association.
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Effects and 95% confidence intervals of genetically predicted AAM on risks for various sex-
steroid-sensitive cancers, adjusted for the effects of the same AAM variants on BMI. AAM 
was predicted by all 375 autosomal AAM-associated SNPs, and models were adjusted for 
the genetic effects of the same AAM variants on BMI. Three further genetic score 
associations are shown as sensitivity analyses for each outcome: first, AAM predicted by the 
314 AAM-associated SNPs that were not also associated with BMI in the BCAC iCOGS 
sample (at a nominal level of P < 0.05); second, AAM predicted by the 61 AAM-associated 
SNPs that were also associated with BMI in this sample; and, third, AAM predicted by all 
375 autosomal AAM-associated SNPs (unadjusted for BMI).
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